Bionano Genomics (BNGO) Change in Accured Expenses (2017 - 2026)

Bionano Genomics has disclosed Change in Accured Expenses across 10 years of filings, most recently posting -$1.4 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$1.4 million, down 190.37% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.5 million (up 74.42% YoY), and the FY2025 annual result was -$580000.0, up 74.06% from the prior year.
• Change in Accured Expenses came in at -$1.4 million for Q1 2026 at Bionano Genomics, down from $522000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.5 million in Q3 2022 to a low of -$5.3 million in Q2 2024.
• The 5-year median for Change in Accured Expenses is -$546000.0 (2024), against an average of -$375823.5.
• Across the five-year window, Change in Accured Expenses sank 1073.1% in 2022 and jumped 424.54% in 2024, its largest moves.
• Bionano Genomics' Change in Accured Expenses stood at -$1.7 million in 2022, then slumped by 105.11% to -$3.5 million in 2023, then surged by 84.35% to -$546000.0 in 2024, then soared by 195.6% to $522000.0 in 2025, then plunged by 371.46% to -$1.4 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.4 million (Q1 2026), $522000.0 (Q4 2025), and $721000.0 (Q3 2025), per Business Quant data.